GMT

Dalata Hotel Group PLC: NOR-Notice of Results

Retrieved on: 
Friday, February 9, 2024
Webcast, GMT, Cryptocurrency

Dublin and London | 9 February 2024: Dalata Hotel Group plc ("Dalata" or "the Group"), the largest hotel operator in Ireland, with a growing presence in the United Kingdom and continental Europe, announces it will release 2023 Full Year Results on Thursday 29th February 2024 at 07.00 GMT.

Key Points: 
  • Dublin and London | 9 February 2024: Dalata Hotel Group plc ("Dalata" or "the Group"), the largest hotel operator in Ireland, with a growing presence in the United Kingdom and continental Europe, announces it will release 2023 Full Year Results on Thursday 29th February 2024 at 07.00 GMT.
  • The senior management team will host a conference call and webcast for analysts and investors at 08.30 GMT on this date.
  • Please allow sufficient time for registration.
  • The Group’s Full Year Results, press release and presentation will also be available on the Dalata website on 29th February 2024 https://dalatahotelgroup.com

A clearer vision for surgical robotics: CMR Surgical announces significant update to Versius

Retrieved on: 
Thursday, February 8, 2024
Surgeon, CMR, ICG, General surgery, 3D, Bose, Patient, Indocyanine green, CMR Surgical, Minimally invasive procedure, GMT, Contraindication, Communication, Thought, Sale, CE, Health, Eye, Gloucestershire Royal Hospital, Anatomy, MAS, Fatigue

CMR Surgical (CMR) – the global surgical robotics business – has today announced the launch of vLimeLite – an integrated fluorescence imaging system to visualise ICG (Indocyanine green), which will give surgeons enhanced visualisation, where indicated.

Key Points: 
  • CMR Surgical (CMR) – the global surgical robotics business – has today announced the launch of vLimeLite – an integrated fluorescence imaging system to visualise ICG (Indocyanine green), which will give surgeons enhanced visualisation, where indicated.
  • Supratim Bose, Chief Executive Officer of CMR Surgical, commented: “With 3D HD visualisation, surgeons already have a fantastic view of their operating field at our Versius console.
  • As long-term partners of CMR, we were delighted to be the first to get our hands on its ICG system.
  • Through the Versius Connect app, Versius Trainer and CMR clinical registry, Versius unleashes a wealth of insights to ultimately improve surgical care.

A clearer vision for surgical robotics: CMR Surgical announces significant update to Versius

Retrieved on: 
Thursday, February 8, 2024
Surgeon, CMR, ICG, General surgery, 3D, Bose, Patient, Indocyanine green, CMR Surgical, Minimally invasive procedure, GMT, Contraindication, Communication, Thought, Sale, CE, Health, Eye, Gloucestershire Royal Hospital, Anatomy, MAS, Fatigue

CMR Surgical (CMR) – the global surgical robotics business – has today announced the launch of vLimeLite – an integrated fluorescence imaging system to visualise ICG (Indocyanine green), which will give surgeons enhanced visualisation, where indicated.

Key Points: 
  • CMR Surgical (CMR) – the global surgical robotics business – has today announced the launch of vLimeLite – an integrated fluorescence imaging system to visualise ICG (Indocyanine green), which will give surgeons enhanced visualisation, where indicated.
  • Supratim Bose, Chief Executive Officer of CMR Surgical, commented: “With 3D HD visualisation, surgeons already have a fantastic view of their operating field at our Versius console.
  • As long-term partners of CMR, we were delighted to be the first to get our hands on its ICG system.
  • Through the Versius Connect app, Versius Trainer and CMR clinical registry, Versius unleashes a wealth of insights to ultimately improve surgical care.

Middleby Acquires GBT GmbH Bakery Technology

Retrieved on: 
Wednesday, February 7, 2024
Restaurant, Bar, Food, Beverage, Manufacturing, Other Manufacturing, Retail, MIDD, GBT, GMT, Middleby Corporation, Bread, Engineering, Acquisition

The Middleby Corporation (NASDAQ: MIDD) today announced the acquisition of GBT GmbH Bakery Technology (GBT).

Key Points: 
  • The Middleby Corporation (NASDAQ: MIDD) today announced the acquisition of GBT GmbH Bakery Technology (GBT).
  • “GBT customizable equipment highly complements our existing bakery brands and allows us to strengthen our European presence in large scale baking,” said Tim FitzGerald, CEO of Middleby.
  • “The company brings German engineering capabilities and a broad knowledge of full line bakery solution integration to Middleby.
  • The systems, products and services offered by GMT will enhance the capabilities of Middleby Bakery full line solutions.

EQS-News: MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value

Retrieved on: 
Tuesday, February 6, 2024
Slate, Partnership, Supervisory board, Centerview Partners, Immediate, Novartis, Tender offer, Tafasitamab, Purchasing, EZH2, Ruxolitinib, Patient, BET, Workforce, GMT, EZH1, Federal Financial Supervisory Authority, Disease, Acquisition, AG, EST, Business analyst, Webcast, Cancer, Schedule, Pharmaceutical industry

Separately, MorphoSys entered into a Purchase Agreement to sell and transfer all rights worldwide related to tafasitamab to Incyte Corporation (“Incyte”).

Key Points: 
  • Separately, MorphoSys entered into a Purchase Agreement to sell and transfer all rights worldwide related to tafasitamab to Incyte Corporation (“Incyte”).
  • “Novartis shares our steadfast commitment to develop and deliver transformative medicines that address the dire needs of cancer patients.
  • Novartis intends to offer MorphoSys’ shareholders € 68.00 per share in cash, for a total equity value of € 2.7 billion.
  • Creates New Opportunities for MorphoSys’ Colleagues: The agreement between Novartis and MorphoSys includes employee commitments.

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster

Retrieved on: 
Monday, February 5, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Clinical Trials, Pfizer–BioNTech COVID-19 vaccine, SARS-CoV-2, Senior, RNA, Arcturus, ARCT, GMT, Messenger, CSL, Therapy, ASX, Arcturus Therapeutics, Vaccine

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the results of a follow-up analysis of a Phase 3 study evaluating a booster dose of ARCT-154, the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine, compared to a conventional mRNA COVID-19 vaccine.

Key Points: 
  • Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the results of a follow-up analysis of a Phase 3 study evaluating a booster dose of ARCT-154, the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine, compared to a conventional mRNA COVID-19 vaccine.
  • ARCT-154 was administered at one-sixth the dose of Comirnaty® (5 μg vs 30 μg, respectively).
  • “These results further support sa-mRNA’s differentiating attribute to provide prolonged protection against COVID-19 at lower doses,” said Jonathan Edelman, M.D., Senior Vice President, Vaccines Innovation Unit, CSL.
  • GMTs against Wuhan-Hu-1 remained numerically higher 180 days after ARCT-154 than those observed 28 days after the Comirnaty® booster.

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster

Retrieved on: 
Monday, February 5, 2024
Pfizer–BioNTech COVID-19 vaccine, COVID-19, SARS-CoV-2, SAN, Senior, RNA, Arcturus, ARCT, GMT, Messenger, CSL, Therapy, ASX, Arcturus Therapeutics, Vaccine

KING OF PRUSSIA, Pa. and SAN DIEGO, Feb. 5, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the results of a follow-up analysis of a Phase 3 study evaluating a booster dose of ARCT-154 , the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine, compared to a conventional mRNA COVID-19 vaccine. ARCT-154 was administered at one-sixth the dose of Comirnaty® (5 μg vs 30 μg, respectively).

Key Points: 
  • ARCT-154 was administered at one-sixth the dose of Comirnaty® (5 μg vs 30 μg, respectively).
  • The new analysis at 6 months post-vaccination shows that ARCT-154 induces a longer immune response as compared to Comirnaty for both the original Wuhan strain and Omicron BA.4/5 variant and an advantage in antibody persistence.
  • "These results further support sa-mRNA's differentiating attribute to provide prolonged protection against COVID-19 at lower doses," said Jonathan Edelman, M.D., Senior Vice President, Vaccines Innovation Unit, CSL.
  • GMTs against Wuhan-Hu-1 remained numerically higher 180 days after ARCT-154 than those observed 28 days after the Comirnaty® booster.

HUTCHMED to Announce 2023 Final Results

Retrieved on: 
Thursday, February 1, 2024
HCM, HKT, Q&A, EST, GMT, Standard Chinese, Broadcasting

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2023 on Wednesday, February 28, 2024 at 6:30 am Eastern Standard Time (EST) / 11:30 am Greenwich Mean Time (GMT) / 7:30 pm Hong Kong Time (HKT).

Key Points: 
  • HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2023 on Wednesday, February 28, 2024 at 6:30 am Eastern Standard Time (EST) / 11:30 am Greenwich Mean Time (GMT) / 7:30 pm Hong Kong Time (HKT).
  • Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management.
  • The English conference call and audio webcast will take place at 7:30 am EST / 12:30 pm GMT / 8:30 pm HKT on Wednesday, February 28, 2024.
  • Details of the conference call dial-in will be provided in the financial results announcement and on the company website.

Alcatel-Lucent Enterprise Hosts Connex24, Its Global Partner Conference

Retrieved on: 
Thursday, February 1, 2024
Security, Technology, Telecommunications, Mobile, Wireless, Software, Networks, Internet, Enterprise, Education, Partner, Alcatel-Lucent Enterprise, Government, GMT, Transport, Senior, Communication, Health, Network equipment provider

Alcatel-Lucent Enterprise , a leading provider of communications, cloud and networking solutions tailored to customers’ industries, is hosting its annual global partner conference from 7th-8th February 2024.

Key Points: 
  • Alcatel-Lucent Enterprise , a leading provider of communications, cloud and networking solutions tailored to customers’ industries, is hosting its annual global partner conference from 7th-8th February 2024.
  • Claudio Soland, Senior Vice President, Global Go-to-Market (GMT) & Services, Alcatel-Lucent Enterprise comments:
    "Alcatel-Lucent Enterprise is dedicated to embracing our customers' digital transformations alongside our business partners.
  • Recognising a growing trend in collaborative partner eco-systems, we're actively fostering a model that unleashes powerful synergies among diverse partners.
  • Alcatel-Lucent Enterprise is dedicated to supporting its global ecosystem of 3,400 business partners and its worldwide base of over a million customers.

Disposal of interests in Acacia Estates and Bora Africa to the group’s development subsidiary, Gateway Real Estate Africa

Retrieved on: 
Tuesday, January 30, 2024
Grand-Baie, Common stock, GSL, DFI, Sale, PIC, Health, GMT, Growth, APDM, Precinct, Unity Building, MUT, ESG, Recycling, World Bank Group, Person, NAV, Investment, Social group, Proxy, International Finance Corporation, Government, Mass meeting, Resolution, Security (finance)

Another part of the Grit 2.0 strategy is to organise the Group's real estate assets into logical sector groupings.

Key Points: 
  • Another part of the Grit 2.0 strategy is to organise the Group's real estate assets into logical sector groupings.
  • Bora Africa has a pipeline of predominantly development opportunities, which GSL does not currently have the capital to develop.
  • of the enlarged issued share capital in Bora Africa (the "Bora Subscription") for an aggregate subscription price of US$9,999 (the "Bora Subscription Price").
  • Following the Bora Investment, Bora Africa will use the proceeds to repay the GSL/Bora Loan in full.